Related Experiment Video
Updated: Aug 2, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Prostate-specific antigen: the new early detection test for prostate cancer
The Nurse Practitioner
|May 1, 1993
Summary
Early prostate cancer detection is vital for survival. Combining prostate-specific antigen (PSA) tests with digital rectal exams significantly improves early detection rates in men aged 50 and older.
Area of Science:
- Urology
- Oncology
- Medical Diagnostics
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Early detection significantly improves survival rates and treatment outcomes.
- Digital rectal exam (DRE) alone is insufficient for adequate early detection.
Purpose of the Study:
- To outline current prostate cancer screening guidelines.
- To explain the interpretation of serum prostate-specific antigen (PSA) test results.
- To present an algorithm for managing abnormal PSA test findings.
Main Methods:
- Review of current American Cancer Society screening recommendations.
- Description of serum PSA assay principles and interpretation.
- Development of a follow-up algorithm for abnormal PSA levels.
Main Results:
- Annual serum PSA testing, combined with DRE, is recommended for men aged 50+.
- Serum PSA assay is emerging as a standard early detection tool alongside DRE.
- Evidence supports the combined approach for increased early detection rates.
Conclusions:
- The combination of serum PSA testing and DRE enhances early prostate cancer detection.
- Adherence to updated screening guidelines and follow-up protocols is crucial.
- Effective interpretation and management of PSA results can improve patient outcomes.
